newsfilter
← Latest News
GlobeNewswire·

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo safety concerns observed in any age group by an independent Data Monitoring Committee